Antigen Identified By Monoclonal antibody Ki-67 (MKI67) antibody

Antigen: Antigen Identified By Monoclonal Antibody Ki-67 (MKI67)

Synonyms: KIA, Ki67, Ki-67, D630048A14Rik, MKI67, kia, mki67, MGC132156

Clonality: Monoclonal (MB67)

Host: Mouse

Reactivity: Human

Application: Immunohistochemistry (IHC)

Catalog no.: ABIN125344

Additional Information

Alternative name: Ki-67 Antigen

Immunogen: Human recombinant Ki-67 protein corresponding to a 1086bp Ki67 motif-containing fragment.

Format: Ig-fraction

Isotype: IgG1

Clone: MB67

Specificity: This antibody reacts with Ki-67 antigen associated with cell proliferation and found throughout the cell cycle (G1, S, G2, M) but absent in resting cells. This antibody is useful in the study of cell proliferation in neoplastic cell populations and with stimulated lymphocytes. It may be used in establishing the growth fraction of neoplasms.

Application Details

Application Notes: Titer/Working Dilution: This antibody may be diluted to a titer of 1:25-1:50 in an ABC method. However, depending on the staining conditions employed, we suggest that final dilution should be determined by the user. Staining Protocol: We suggest an incubation period of 30 minutes at room temperature. However, depending upon the fixation conditions and the staining system employed, optimal incubation should be determined by the user. High temperature treatment of formalin-fixed tissue sections with 10mM citrate buffer, pH 6.0 must be performed prior to the immunostaining. Positive Control: Tonsil. Cellular localization: Nuclear

Concentration: 100ug/ml approximately

Buffer: This antibody is supplied as purified by protein G chromatography containing sodium azide as preservative.

Storage: Store the antibody at 2-8o c. Do not use it beyond the expiration date stated on the label.

Research Area: Proliferation Markers, Cell Cycle

Restrictions: For Research Use. CE-certified for In Vitro Diagnostics (IVD) Use in the European Union

Publications

Publications: Bhattacharya, Tuoth, Durrani et al.: "Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts." in: Neoplasia (New York, N.Y.), Vol. 10, Issue 8, pp. 857-65, 2008 (PubMed).